Cargando…

Changes in clinical disease activity are weakly linked to changes in MRI inflammation on treat-to-target escalation of therapy in rheumatoid arthritis

BACKGROUND: Rheumatoid arthritis (RA) treat-to-target (T2T) regimens often use the disease activity score (28 joints) incorporating C-reactive protein (DAS28(CRP)) as an outcome measure. We compared changes in the DAS28(CRP) with changes in magnetic resonance imaging (MRI) inflammation on treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: McQueen, Fiona M., Chapman, Peter, Pollock, Terina, D’Souza, Dena, Lee, Arier C., Dalbeth, Nicola, Stamp, Lisa, Lindsay, Karen, Doyle, Anthony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655857/
https://www.ncbi.nlm.nih.gov/pubmed/29065903
http://dx.doi.org/10.1186/s13075-017-1433-7
_version_ 1783273616595484672
author McQueen, Fiona M.
Chapman, Peter
Pollock, Terina
D’Souza, Dena
Lee, Arier C.
Dalbeth, Nicola
Stamp, Lisa
Lindsay, Karen
Doyle, Anthony
author_facet McQueen, Fiona M.
Chapman, Peter
Pollock, Terina
D’Souza, Dena
Lee, Arier C.
Dalbeth, Nicola
Stamp, Lisa
Lindsay, Karen
Doyle, Anthony
author_sort McQueen, Fiona M.
collection PubMed
description BACKGROUND: Rheumatoid arthritis (RA) treat-to-target (T2T) regimens often use the disease activity score (28 joints) incorporating C-reactive protein (DAS28(CRP)) as an outcome measure. We compared changes in the DAS28(CRP) with changes in magnetic resonance imaging (MRI) inflammation on treatment escalation. METHODS: Eighty seropositive RA patients with active disease were enrolled. Group A (N = 57) escalated to another conventional disease-modifying therapy (cDMARD) combination, and Group B (N = 23) to anti-TNF therapy/cDMARDs. Contrast-enhanced 3T-MRI wrist scans were obtained before and 4 months after regimen change. Scan pairs were scored for inflammation (MRI(i)) and damage. Disease activity was assessed using the DAS28(CRP). RESULTS: Eighty patients were enrolled and 66 MRI scan pairs were available for analysis. Intra-reader reliability was high: intraclass correlation coefficient (average) 0.89 (0.56–0.97). ΔDAS28(CRP) did not differ between groups: Group A, −0.94 (−3.30, 1.61); Group B, −1.53 (−3.59, 0.56) (p = 0.45). ΔMRI(i) also did not differ: Group A, 0 (−25, 10); Group B, −1 (−15, 28) (p = 0.12). Combining groups, ΔMRI(i) correlated weakly with ΔDAS28(CRP) (Spearman’s 0.36, p = 0.003). Using multiple linear regression analysis adjusting for confounders, ΔDAS28(CRP) was associated with ΔMRI(i) (p = 0.056). Of the individual MRI measures, only Δtenosynovitis correlated with ΔDAS28(CRP) (Spearman’s 0.33, p = 0.007). ΔMRI(i) was negatively associated with the MRI erosion score at entry (p = 0.0052). CONCLUSIONS: We report the first study investigating the link between changes in clinical and imaging inflammation in a real-world RA cohort escalating to conventional and biologic DMARDs. The association was significant but relatively weak, suggesting that MRI targets cannot yet be advocated as outcomes for T2T escalation. TRIAL REGISTRATION: ANZCTR 12614000895684. Registered 22 August 2014.
format Online
Article
Text
id pubmed-5655857
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-56558572017-10-31 Changes in clinical disease activity are weakly linked to changes in MRI inflammation on treat-to-target escalation of therapy in rheumatoid arthritis McQueen, Fiona M. Chapman, Peter Pollock, Terina D’Souza, Dena Lee, Arier C. Dalbeth, Nicola Stamp, Lisa Lindsay, Karen Doyle, Anthony Arthritis Res Ther Research Article BACKGROUND: Rheumatoid arthritis (RA) treat-to-target (T2T) regimens often use the disease activity score (28 joints) incorporating C-reactive protein (DAS28(CRP)) as an outcome measure. We compared changes in the DAS28(CRP) with changes in magnetic resonance imaging (MRI) inflammation on treatment escalation. METHODS: Eighty seropositive RA patients with active disease were enrolled. Group A (N = 57) escalated to another conventional disease-modifying therapy (cDMARD) combination, and Group B (N = 23) to anti-TNF therapy/cDMARDs. Contrast-enhanced 3T-MRI wrist scans were obtained before and 4 months after regimen change. Scan pairs were scored for inflammation (MRI(i)) and damage. Disease activity was assessed using the DAS28(CRP). RESULTS: Eighty patients were enrolled and 66 MRI scan pairs were available for analysis. Intra-reader reliability was high: intraclass correlation coefficient (average) 0.89 (0.56–0.97). ΔDAS28(CRP) did not differ between groups: Group A, −0.94 (−3.30, 1.61); Group B, −1.53 (−3.59, 0.56) (p = 0.45). ΔMRI(i) also did not differ: Group A, 0 (−25, 10); Group B, −1 (−15, 28) (p = 0.12). Combining groups, ΔMRI(i) correlated weakly with ΔDAS28(CRP) (Spearman’s 0.36, p = 0.003). Using multiple linear regression analysis adjusting for confounders, ΔDAS28(CRP) was associated with ΔMRI(i) (p = 0.056). Of the individual MRI measures, only Δtenosynovitis correlated with ΔDAS28(CRP) (Spearman’s 0.33, p = 0.007). ΔMRI(i) was negatively associated with the MRI erosion score at entry (p = 0.0052). CONCLUSIONS: We report the first study investigating the link between changes in clinical and imaging inflammation in a real-world RA cohort escalating to conventional and biologic DMARDs. The association was significant but relatively weak, suggesting that MRI targets cannot yet be advocated as outcomes for T2T escalation. TRIAL REGISTRATION: ANZCTR 12614000895684. Registered 22 August 2014. BioMed Central 2017-10-24 2017 /pmc/articles/PMC5655857/ /pubmed/29065903 http://dx.doi.org/10.1186/s13075-017-1433-7 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
McQueen, Fiona M.
Chapman, Peter
Pollock, Terina
D’Souza, Dena
Lee, Arier C.
Dalbeth, Nicola
Stamp, Lisa
Lindsay, Karen
Doyle, Anthony
Changes in clinical disease activity are weakly linked to changes in MRI inflammation on treat-to-target escalation of therapy in rheumatoid arthritis
title Changes in clinical disease activity are weakly linked to changes in MRI inflammation on treat-to-target escalation of therapy in rheumatoid arthritis
title_full Changes in clinical disease activity are weakly linked to changes in MRI inflammation on treat-to-target escalation of therapy in rheumatoid arthritis
title_fullStr Changes in clinical disease activity are weakly linked to changes in MRI inflammation on treat-to-target escalation of therapy in rheumatoid arthritis
title_full_unstemmed Changes in clinical disease activity are weakly linked to changes in MRI inflammation on treat-to-target escalation of therapy in rheumatoid arthritis
title_short Changes in clinical disease activity are weakly linked to changes in MRI inflammation on treat-to-target escalation of therapy in rheumatoid arthritis
title_sort changes in clinical disease activity are weakly linked to changes in mri inflammation on treat-to-target escalation of therapy in rheumatoid arthritis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655857/
https://www.ncbi.nlm.nih.gov/pubmed/29065903
http://dx.doi.org/10.1186/s13075-017-1433-7
work_keys_str_mv AT mcqueenfionam changesinclinicaldiseaseactivityareweaklylinkedtochangesinmriinflammationontreattotargetescalationoftherapyinrheumatoidarthritis
AT chapmanpeter changesinclinicaldiseaseactivityareweaklylinkedtochangesinmriinflammationontreattotargetescalationoftherapyinrheumatoidarthritis
AT pollockterina changesinclinicaldiseaseactivityareweaklylinkedtochangesinmriinflammationontreattotargetescalationoftherapyinrheumatoidarthritis
AT dsouzadena changesinclinicaldiseaseactivityareweaklylinkedtochangesinmriinflammationontreattotargetescalationoftherapyinrheumatoidarthritis
AT leearierc changesinclinicaldiseaseactivityareweaklylinkedtochangesinmriinflammationontreattotargetescalationoftherapyinrheumatoidarthritis
AT dalbethnicola changesinclinicaldiseaseactivityareweaklylinkedtochangesinmriinflammationontreattotargetescalationoftherapyinrheumatoidarthritis
AT stamplisa changesinclinicaldiseaseactivityareweaklylinkedtochangesinmriinflammationontreattotargetescalationoftherapyinrheumatoidarthritis
AT lindsaykaren changesinclinicaldiseaseactivityareweaklylinkedtochangesinmriinflammationontreattotargetescalationoftherapyinrheumatoidarthritis
AT doyleanthony changesinclinicaldiseaseactivityareweaklylinkedtochangesinmriinflammationontreattotargetescalationoftherapyinrheumatoidarthritis